Published on September 5, 2009 at 3:59 AM
ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed a Technology Co-Development Agreement with its primary cell preparation and application technology supplier. The co-development agreement calls for the joint-development of a fully integrated chromosomal scanner system for nation-wide distribution to pathology and related cancer detection labs.
The agreement calls for the technical collaboration and partnership between the companies and joint technical research and development efforts to complete a fully automated hybridization system allowing for a complete 'end-to-end' chromosomal scanning solution. The company has named the system "CS300" and represents a significant advancement in automating every aspect of the preparation and scanning cycles of the CS200's current automation capabilities and design.
The feature set of the new system is anticipated to include:
-- Ability to perform a full 23-pair chromosomal cross-sectioning for every cell within a sample -- Integration of solid tissue disaggregation inputs and automation -- Integration for inputs derived from de-paraffinization protocols for histo-pathology research and patient tissue archive recovery and assay -- Parallel DNA-probe insertions across hybridizing channels for rapid scans across multiple chromosomes -- Ability to integrate solid tumor incubation equipment for therapeutic and cancer cure protocols testing.
The remainder of the Company's plan of operations for 2009 will continue to be executed and investors updated accordingly.
Updates will be timely published on the following:
-- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Additional appointments to the Company's Advisory Boards -- Acquisition of profitable labs to expand the company's operations -- Release of technology and industry White Papers.
SOURCE: ChromoCure, Inc.